natgillin/translations-raw huggingface dataset:
infestationer
infestations
Inflacam 1 mg tuggtabletter för hund Inflacam 2,5 mg tuggtabletter för hund
Inflacam 1 mg chewable tablets for dogs Inflacam 2.5 mg chewable tablets for dogs
Inflacam 1 mg tuggtabletter för hund Inflacam 2,5 mg tuggtabletter för hund Meloxikam
Inflacam 1 mg chewable tablets for dogs Inflacam 2.5 mg chewable tablets for dogs Meloxicam
Inflacam 1,5 mg/ml oral suspension för hund
Inflacam 1.5 mg/ml oral suspension for dogs
Inflacam 1,5 mg/ml oral suspension för hund Meloxikam
Inflacam 1.5 mg/ml oral suspension for dogs Meloxicam
Inflacam 1,5 mg/ml oral suspension till hund eller Inflacam 1 mg och 2,5 mg tuggtabletter till hund kan användas för förlängning av behandlingen med en dos på 0,1 mg meloxikam/kg kroppsvikt, 24 timmar efter administration av injektion.
Inflacam 1.5 mg/ml oral suspension for dogs or Inflacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.
Inflacam 15 mg/ml oral suspension för häst
Inflacam 15 mg/ml oral suspension for horses
Inflacam 15 mg/ml oral suspension för häst Meloxikam
Inflacam 15 mg/ml oral suspension for horses Meloxicam
Inflacam 20 mg/ml injektionsvätska, lösning för nötkreatur, svin och häst
Inflacam 20 mg/ml solution for injection for cattle, pigs and horses
Inflacam 20 mg/ml injektionsvätska, lösning för nötkreatur, svin och häst Meloxikam
Inflacam 20 mg/ml solution for injection for cattle, pigs and horses Meloxicam
Inflacam 330 mg granulat för häst
Inflacam 330 mg granules for horses
Inflacam 330 mg granulat för häst meloxikam
Inflacam 330 mg, granules for horses. meloxicam
Inflacam 5 mg/ml injektionsvätska, lösning för hund och katt
Inflacam 5 mg/ml solution for injection for dogs and cats
Inflacam 5 mg/ml injektionsvätska, lösning för hund och katt Meloxikam
Inflacam 5 mg/ml solution for injection for cats and dogs Meloxicam
Inflacam 5 mg/ml injektionsvätska, lösning för hund och katt Meloxikam
Inflacam 5 mg/ml solution for injection for dogs and cats Meloxicam
Inflacam 5 mg/ml injektionsvätska, lösning för hund och katt.
Inflacam 5 mg/ml solution for injection for dogs and cats
Inflacam 5 mg/ml injektionsvätska, lösning för nötkreatur och svin
Inflacam 5 mg/ml solution for injection for cattle and pigs
Inflacam 5 mg/ml injektionsvätska, lösning för nötkreatur och svin Meloxikam
Inflacam 5 mg/ml solution for injection for cattle and pigs Meloxicam
Inflacam skall inte administreras samtidigt med andra NSAIDs eller glukokortikosteroider.
Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteriods.
Inflacam skall inte administreras samtidigt med andra NSAIDs eller glukokortikosteroider.
Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Inflacam tuggtabletter kan ges både tillsammans med eller utan foder, är smaksatta och intas frivilligt av de flesta hundar.
Inflacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Inflacam е ВМП, който съдържа активната субстанция мелоксикам (meloxicam).
Inflacam is a medicine that contains the active substance meloxicam.
Inflacam е „генеричен ВМП“.
Inflacam is a ‘generic medicine’.
Inflacam се предлага под формата на гранули в сашета (330 mg), перорални суспензии (1,5 mg/ml и 15 mg/ml), таблетки за дъвчене (1 mg и 2,5 mg) и инжекционен разтвор (5 mg/ml и 20 mg/ml).
Inflacam is available as granules in sachets (330 mg), oral suspensions (1.5 mg/ml and 15 mg/ml), chewable tablets (1 mg and 2.5 mg) and solution for injection (5 mg/ml and 20 mg/ml).
Inflacam съдържа мелоксикам, който принадлежи към класа лекарства, наричани нестероидни противовъзпалителни средства (НСПВС).
Inflacam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Inflammationsdämpande och smärtlindrande användning vid såväl akuta som kroniska sjukdomar i muskler, leder och skelett.
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Inflammationsdämpande och smärtlindrande vid såväl akuta som kroniska muskuloskeletala sjukdomstillstånd.
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
Inflectra 100 mg прах за концентрат за инфузионен разтвор Инфликсимаб
Inflectra 100 mg powder for concentrate for solution for infusion Infliximab
Inflectra е показан за лечение на тежка болест на Crohn в активен стадий при деца и юноши на възраст от 6 до 17 години, които не са отговорили на стандартна терапия, включваща кортикостероид, имуномодулатор и първична хранителна терапия или които проявяват непоносимост, или при които има противопоказания за такава терапия.
Inflectra is indicated for treatment of severe, active Crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Inflectra е показан за лечение на тежък активен улцерозен колит при деца и юноши на възраст от 6 до 17 години, с недостатъчен отговор на стандартна терапия, включително с кортикостероиди и 6-MP или AZA, или такива при които има непоносимост към или медицински противопоказания за такава терапия.
Inflectra is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
Inflectra е показан за лечение на умерено тежък до тежък псориазис с плаки при възрастни пациенти, които не отговарят, имат противопоказания или непоносимост към лечение с други системни препарати, включително циклоспорин, метотрексат или псорален ултравиолет-А (psoralen ultra-violet A – PUVA) (вж. точка 5.1).
Inflectra is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1).
Inflectra е „биоподобно“ лекарство.
‘Inflectra is a ‘biosimilar’ medicine.
Inflectra може да се съхранява при температура максимум 25°C еднократно за период до месеца, но не и след датата на изтичане на първоначалния срок на годност.
Inflectra may be stored at temperatures up to a maximum of 25 °C for a single period of up to 6 months, but not exceeding the original expiry date.
Inflectra не е проучван при тези пациентски популации.
Inflectra has not been studied in these patient populations.
Inflectra не трябва да се продължава при пациенти, при които се развие или се влоши съществуваща сърдечна недостатъчност (вж. точки 4.3 и 4.8).
Patients should be closely monitored and Inflectra must not be continued in patients who develop new or worsening symptoms of heart failure (see sections 4.3 and 4.8).
Inflectra принадлежи към група лекарства, наречени „инхибитори на TNF”.
Inflectra belongs to a group of medicines called ‘TNF blockers’.
Inflectra се доставя в стъклени флакони, съдържащи прах за концентрат за инфузионен разтвор.
Inflectra is supplied as a glass vial containing a powder for concentrate for solution for infusion.
Inflectra се произвежда в опаковки от 1, 2, 3, 4 или 5 флакона.
Inflectra is produced in packs of 1, 2, 3, 4 and 5 vials.
Inflectra се произвежда по метод, познат като „рекомбинантна ДНК технология“.
Inflectra is produced by a method known as ‘recombinant DNA technology’.
Inflectra съдържа активното вещество, наречено инфликсимаб.
Inflectra contains the active substance called infliximab.
Inflectra съдържа натрий
Inflectra contains Sodium
Inflectra трябва да се прилага едновременно с метотрексат.
Inflectra must be given concomitantly with methotrexate.
Inflectra трябва да се прилага интравенозно за период от 2 часа.
Inflectra should be administered intravenously over a 2 hour period.
Inflectra трябва да се прилага с повишено внимание при пациенти с лека сърдечна недостатъчност (I/II ФК по NYHA).
Inflectra should be used with caution in patients with mild heart failure (NYHA class I/II).
Inflectra трябва да се прилага:
Inflectra should be administered
Inflectra ще Ви бъде прилаган в болница или клиника от лекар или медицинска сестра.
Inflectra will be given to you by your doctor or nurse, in a hospital or clinic.
Inflectra ще бъде съхраняван от медицинските специалисти в болницата или клиниката.
Inflectra will be stored by the health professionals at the hospital or clinic.
Inflectra, в комбинация с метотрексат, е показан за намаляване на признаците и симптомите, както и постигане на подобрение във физическата функция, при: възрастни пациенти с активна болест с недостатъчен отговор на лечението с модифициращи болестта антиревматоидни средства (DMARD), включително и метотрексат. възрастни пациенти с тежка, активна и прогресираща болест, които не са лекувани с метотрексат или други DMARD.
Inflectra, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate. adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
Influenza A/eq/Ohio/03 [H3N8] (vCP2242) ............................................................. ≥ 5.3 log10 FAID50
Influenza A/eq/Ohio/03 [H3N8] (vCP2242) ...............................................................≥ 5.3 log10 FAID50
Influenza A/eq/Ohio/03 [H3N8] (vCP2242)............................................................... ≥ 5.3 log10 FAID50
Influenza A/eq/Ohio/03 [H3N8] (vCP2242) ............................................................. ≥ 5.3 log10 FAID50
Influenza A/eq/Ohio/03 [H3N8] рекомбинантен Canarypox вирус (vCP2242) .... ≥ 5.3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] рекомбинантен Canarypox вирус ........... ≥ 5.3 log10 FAID50* Clostridium tetani токсоид ...................................................................................................... ≥ 30 IU**
Influenza A/eq/Ohio/03 [H3N8] recombinant canarypox virus (vCP2242) ...........≥ 5.3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] recombinant canarypox virus (vCP3011) ≥ 5.3 log10 FAID50* Clostridium tetani toxoid ......................................................................................................... ≥ 30 IU
Influenza A/eq/Richmond/1/07 [H3N8] (vCP1533)................................................... ≥ 5.3 log10 FAID50
Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011) ................................................. ≥ 5.3 log10 FAID50
Influenza A/eq/Richmond/1/07[H3N8] (vCP3011) ................................................... ≥ 5.3 log10 FAID50
Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011) ...................................................≥ 5.3 log10 FAID50
Info.ee@sandoz.com Tlf: + 45 6395 1000 variations.nordic@sandoz.com
Tlf: + 45 6395 1000 variations.nordic@sandoz.com
info@ratiopharm.de
Germany info@ratiopharm.de
Infolehe sisukord
What is in this leaflet
Infoleht on viimati kooskõlastatud
This leaflet was last approved in {MM/YYYY}.
Infomed@viivkealthcare.com
Infomed@viivhealthcare.com
INFORMACE V BRAILLOVĚ PÍSMU
INFORMATION IN BRAILLE
Informaci, jak si stanovit cílové hodnoty kalorií a tuků si přečtěte v Dalších užitečných informacích v modrých stránkách v bodu 6.
For information on how to set your calorie and fat targets, see Further helpful information in the blue pages in section 6.
Informacije o nadzorovanju koncentracije NO2 boste našli v poglavju 4.2.
See section 4.2 for information on monitoring for NO2.
INFORMATION I PUNKTSKRIFT
INFORMATION IN BRAILLE
Information om hur du rapporterar biverkningar finns i slutet av avsnitt 4.
See the end of section 4 for how to report side effects.
Informera din läkare om du får någon av följande biverkningar: De vanligaste biverkningarna
Tell your doctor about any of the following side effects: Most frequent side effects
Informera din läkare om du sedan tidigare har eller har haft en leversjukdom, inklusive hepatit.
Talk to your doctor if you have a history of liver disease, including hepatitis.
Informera din läkare om du tidigare har haft njursjukdomar eller om prover har visat att du har problem med njurarna.
Tell your doctor if you have had kidney disease, or if tests have shown problems with your kidneys.
Informera din läkare omedelbart om varje nytt och oväntat symtom som uppträder efter avslutad behandling, särskilt symtom som du vanligtvis förknippar med din hepatit B-infektion.
Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.
Informujte prosím svého lékaře, pokud zaznamenáte změnu toho, jak vám tluče srdce (změny srdečního rytmu).
If you notice a change in the way your heart beats (heart rhythm changes), please inform your doctor.
Informujte svého lékaře nebo lékárníka o všech lécích, které užíváte, které jste v nedávné době užíval(a) nebo které možná budete užívat.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Informujte svého lékaře nebo lékárníka o všech lécích, které užíváte, které jste v nedávné době užíval(a), nebo které možná budete užívat.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Informujte svého lékaře o všech lécích, které užíváte nebo jste užíval (a) v nedávné době nebo které možná budete užívat.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Informujte svého lékaře, pokud nemůžete tabletu spolknout vcelku.
Tell your doctor if you cannot swallow the tablet whole.
Informujte svého lékaře, pokud se u Vás objeví kterýkoliv z těchto nežádoucích účinků.
Tell your doctor if you get any of these.
INFORMÁCIE V BRAILLOVOM PÍSME
INFORMATION IN BRAILLE
Infundirati ga je treba najmanj eno uro.
It should be administered over at least one hour.
Infusionslösningens koncentration under beredning och administrering ska inte överstiga 12 mg/ml ceftarolinfosamil.
The infusion solution concentration during preparation and administration should not exceed 12 mg/ml ceftaroline fosamil.
Infusionstid
Infusion time
Infusionstid (minuter)
(minutes)
Infusionsvolymer för pediatriska patienter varierar med barnets vikt.
Infusion volumes for paediatric patients will vary according to the weight of the child.
Infusioonipudelit/-kotti tuleb ettevaatlikult pöörata, et lahjendatud lahus seguneks, kuid seda EI tohi loksutada, vältimaks vahu teket.
The infusion bottle/bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming.
Infuzijska raztopina zdravila STELARA 130 mg se pripravi iz števila vial, kot je navedeno v preglednici 1 (za pripravo glejte poglavje 6.6).
The infusion solution is to be composed of the number of vials of STELARA 130 mg as specified in Table 1 (see section 6.6 for preparation).
Inga data finns tillgängliga från djurstudier med ceftazidim.
No data are available on animal studies with ceftazidime.
Inga data finns tillgängliga för att ge en dosrekommendation för pediatriska patienter med njurinsufficiens.
No data are available on which to make a dose recommendation in paediatric patients with renal insufficiency.
Inga data finns tillgängliga om effekten och det finns endast mycket begränsade data om säkerheten av emtricitabin hos spädbarn under 4 månaders ålder.
There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age.
Inga data finns tillgängliga.
No data are available.
Inga data har presenterats från fall av överdosering hos vuxna katter.
No data have been presented on overdoses in adult cats.
Inga effekter på den reproduktiva förmågan hos han- eller honråttor har rapporterats.
No effect on the reproductive capacity in male and female rats was noted.
Inga fall av CAP på grund av MRSA rekryterades till studierna.
No cases of CAP due to MRSA were enrolled into the studies.
Inga humandata om effekten av emtricitabin finns tillgängliga.
No human data on the effect of emtricitabine are available.
Inga kliniska interaktionsstudier med andra läkemedel har utförts med ceftarolinfosamil.
No clinical drug-drug interaction studies have been conducted with ceftaroline fosamil.
Inga kliniskt betydelsefulla skillnader i farmakokinetik har observerats med avseende på etnicitet.
No clinically important pharmacokinetic difference due to ethnicity has been identified.
Inga kända.
None known.
Inga studier har utförts av effekten på förmågan att framföra fordon och använda maskiner.
No studies on the effect on the ability to drive and use machines have been performed.
Inga särskilda förvaringsanvisningar krävs för detta veterinärmedicinska läkemedel.
This veterinary medicinal product does not require any special storage conditions.
Inga särskilda förvaringsanvisningar.
SPECIAL STORAGE CONDITIONS
Inga särskilda förvaringsanvisningar.
This veterinary medicinal product does not require any special storage conditions.
Inga uppgifter om överdosering finns för närvarande på djurslag. (Se avsnitt 4.6.)
No information on overdose is currently available in the target species. (See section 4.6.)
Inga uppgifter om överdosering finns för närvarande på djurslag. (Se avsnitt ”Biverkningar”.)
Overdose (symptoms, emergency procedures, antidotes):
Inga.
None.
Ingelvac CircoFLEX е ваксина за прасета, която се предлага под формата на инжекционна суспензия.
Ingelvac CircoFLEX is a vaccine for use in pigs, which is available as a suspension for injection.
Ingelvac CircoFLEX инжекционна суспензия за прасета
Ingelvac CircoFLEX suspension for injection for pigs
Ingelvac CircoFLEX може да причини леко и преходно повишаване на телесната температура, което обикновено настъпва в деня на ваксинацията.
Ingelvac CircoFLEX can cause a mild, temporary increase in body temperature, usually on the day of vaccination.
Ingelvac CircoFLEX се използва за ваксинация на прасета на възраст над 2 седмици срещу инфекция с PCV2.
Ingelvac CircoFLEX is used to vaccinate pigs from two weeks of age against PCV2 infection.
Ingelvac MycoFLEX може да не е разрешен за употреба в някои страни-членки.
Ingelvac MycoFLEX may be not authorised in certain Member States.
Ingen dosjustering anses nödvändig hos patienter med nedsatt leverfunktion (se avsnitt 5.2).
No dosage adjustment is considered necessary in patients with hepatic impairment (see section 5.2).
Ingen dosjustering krävs baserat på kön.
No dose adjustment is required based on gender.
Ingen dosjustering krävs för patienter med nedsatt leverfunktion (se avsnitt 5.2).
No dosage adjustment is required in patients with hepatic impairment (see section 5.2).
Ingen dosjustering krävs för äldre patienter (se avsnitt 5.2).
No dosage adjustment is required in elderly patients (see section 5.2).
Ingen dosjustering är nödvändig för äldre med kreatininclearancevärden > 50 ml/min (se avsnitt 5.2).
No dosage adjustment is required for the elderly with creatinine clearance values > 50 ml/min (see section 5.2).
Ingen känd frekvens
Unknown
Ingen känd frekvens (kan inte beräknas från tillgängliga data)
Frequency not known (cannot be estimated from available data)
Ingen metabolisering av avibaktam observerades i human levervävnad (mikrosomer och hepatocyter).
No metabolism of avibactam was observed in human liver preparations (microsomes and hepatocytes).
Ingen synergi eller antagonism påvisades i in vitro-studier med kombinationer av ceftazidim/avibaktam och metronidazol, tobramycin, levofloxacin, vankomycin, linezolid, kolistin och tigecyklin.
No synergy or antagonism was demonstrated in in vitro drug combination studies with ceftazidime/avibactam and metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline.
INH N = 236, 231, 233, 233, 235, 235, 226, 217, 208, 236.
INH N= 236, 231, 233, 233, 235, 235, 226, 217, 208, 236.
Inhalacijski dušikov oksid se je v predoperacijskem okolju dajal do sedem dni, navadno pa čas zdravljenja traja od 24 do 48 ur.
Inhaled NO has been given for time periods up to 7 days in the peri-operative setting, but common treatment times are 24 -48 hours.
INHALED BETA AGONISTS
cobicistat.
Inhibice metabolizmu zprostředkovaného CYP3A posílená kobicistatem zvyšuje systémovou expozici substrátům CYP3A, jako je např. atazanavir, u nichž je biologická dostupnost omezená a poločas zkrácený v důsledku metabolismu závislém na CYP3A.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A- dependent metabolism.
inhibici CYP3A přípravkem
potential inhibition of CYP3A by
inhibici CYP3A4 atazanavirem
CYP3A4 inhibition by atazanavir
inhibici CYP3A4 atazanavirem a
CYP3A4 inhibition by atazanavir
Inhibitorji CYP2A6
CYP2A6 inhibitors
Inhibitory CYP3A4 a CYP3A5
CYP3A4 and CYP3A5 inhibitors
Inhibitory glykoproteinových receptorů IIb/IIIa: klopidogrel by měl být užíván s opatrností u pacientů s možným rizikem zvýšeného krvácení po traumatu, operaci nebo v důsledku jiných patologických stavů, kteří současně užívají inhibitory glykoproteinu IIb/IIIa (viz bod 4.4).
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions that receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Inhibitory HMG-CoA reduktázy
HMG-CoA reductase inhibitors
Inhibitory integrázy
Integrase Inhibitors
Inhibitory nukleosid/nukleotid reverzní transkriptázy (NRTI)
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Inhibitory PDE5
PDE5 Inhibitors
Inhibitory PDE5 užívané při léčbě poruch erekce
PDE5 inhibitors used for the treatment of erectile dysfunction
Inhibitory proteázy HCV
HCV Protease Inhibitors
Inhibitory proteázy: EVOTAZ se v kombinaci s jinými inhibitory proteázy nedoporučuje, protože souběžné podávání pravděpodobně neposkytuje dostatečnou expozici inhibitoru proteázy.
Protease inhibitors: EVOTAZ in combination with other protease inhibitors is not recommended because co- administration may not provide adequate protease inhibitor exposure.
Inhibitory protonové pumpy
H2 blockers.
Inhixa e „биоподобно“ лекарство.
Inhixa is a ‘biosimilar medicine’.
Injekcijske brizge, igle in viale ne smete ponovno uporabiti.
The syringe, needle and vial must never be re-used.
Injektionsflaska av glas/Injektionsvätska, lösning
Glass vial / Solution for injection
Injektionsflaska av typ I glas om 1 ml (1 dos) eller 10 ml (10 doser), försluten med en halogenbutylgummipropp och förseglad med en kodad aluminiumkapsyl.
Type I glass vial of 1 ml (1 dose) or 10 ml (10 doses) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.
Injektionsflaskan med den rekonstituerade lösningen ska användas omedelbart.
The reconstituted vial should be used immediately.
Injektionsvätska, lösning
Solution for injection
Injektionsvätska, lösning
Solution for injection.
Injektionsvätska, lösning.
Solution for injection
Injektionsvätska, lösning.
Solution for injection.
Injektionsvätska, suspension
Suspension for injection
Injektionsvätskan innehåller 10 mg maropitant per ml som maropitantcitratmonohydrat som en klar, färglös till ljust gul lösning.
The solution for injection contains 10 mg maropitant per ml as maropitant citrate monohydrate as a clear, colourless to light yellow solution.
Injekčnou liekovkou potriasajte do úplného rozpustenia.
Shake the vial until complete dissolution.
Injekčnú liekovkou sa musí potriasať do úplného rozpustenia.
The vial must be shaken until complete dissolution.
Injicirajte si odmerek zdravila:
Inject the dose: